Clinical Trial

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, randomized, controlled, open-label, proof-of-concept study to evaluate the safety and tolerability, local and systemic PK profiles of TNP-2092 administered via IA injection on the basis of vancomycin IV and oral antibiotics therapy in participants with early (within 1 month of TKA) or acute hematogenous (within 3 weeks of infectious symptoms) PJI requiring or not requiring DAIR therapy after TKA, or requiring long-term antibiotic suppression therapy for PJI (including PJI occurring after various joint replacements and revision surgeries).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-19; most recent amendment 2026-03-04.
Status change: Completed → Recruiting 2026-03-04
Status change: Recruiting → Completed 2026-02-28
Status change: Not Yet Recruiting → Recruiting 2025-04-07
Trial Details
NCT Number NCT06889701
Lead Sponsor TenNor Therapeutics Inc.
Collaborators: First Affiliated Hospital of Xinjiang Medical University
Conditions Periprosthetic Joint Infection (PJI)
Enrollment 33 participants
Start Date 2025-04-03
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-05